It began with a Chemical Engineer's theory that industrial lipid management techniques could be used to treat lipid-related diseases in humans.

The application of our Engineering approach to drug development has addressed traditional points-of-failure and produced novel, chemocentric mechanisms of action that target the chemistry, cellular processes and inflammation responsible for Atherosclerosis and NAFLD/NASH.